Public Health Ontario, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.
Euro Surveill. 2019 Mar;24(11). doi: 10.2807/1560-7917.ES.2019.24.11.1800370.
BackgroundGiven that measles is eliminated in Canada and measles immunisation coverage in Ontario is high, it has been questioned whether Ontario's measles outbreak response is worthwhile.AimOur objective was to determine cost-effectiveness of measles containment protocols in Ontario from the healthcare payer perspective.MethodsWe developed a decision-analysis model comparing Ontario's measles containment strategy (based on actual 2015 outbreak data) with a hypothetical 'modified response'. The modified scenario assumed 10% response costs with reduced case and contact tracing and no outbreak-associated vaccinations; it was based on local and provincial administrative and laboratory data and parameters from peer-reviewed literature. Short- and long-term health outcomes, quality-adjusted life years (QALYs) and costs discounted at 1.5%, were estimated. We conducted one- and two-way sensitivity analyses.ResultsThe 2015 outbreak in Ontario comprised 16 measles cases and an estimated 3,369 contacts. Predictive modelling suggested that the outbreak response prevented 16 outbreak-associated cases at a cost of CAD 1,213,491 (EUR 861,579). The incremental cost-effectiveness ratio was CAD 739,063 (EUR 524,735) per QALY gained for the outbreak response vs modified response. To meet the commonly accepted cost-effectiveness threshold of CAD 50,000 (EUR 35,500) per QALY gained, the outbreak response would have to prevent 94 measles cases. In sensitivity analyses, the findings were robust.ConclusionsOntario's measles outbreak response exceeds generally accepted cost-effectiveness thresholds and may not be the most efficient use of public health resources from a healthcare payer perspective. These findings should be balanced against benefits of increased vaccine coverage and maintaining elimination status.
鉴于加拿大已消除麻疹,安大略省的麻疹免疫覆盖率也很高,因此有人质疑安大略省的麻疹疫情应对措施是否值得。
从医疗保健支付者的角度确定安大略省控制麻疹协议的成本效益。
我们开发了一种决策分析模型,比较了安大略省的麻疹控制策略(基于 2015 年实际暴发数据)与假设的“修改后的应对方案”。修改后的方案假设反应成本为 10%,病例和接触者追踪减少,且无暴发相关疫苗接种;该方案基于当地和省级行政和实验室数据以及同行评议文献中的参数。估计了短期和长期健康结果、质量调整生命年(QALY)和贴现率为 1.5%的成本。我们进行了单因素和双因素敏感性分析。
2015 年安大略省暴发涉及 16 例麻疹病例和估计的 3369 名接触者。预测模型表明,疫情应对措施以 1213491 加元(861579 欧元)的成本预防了 16 例暴发相关病例。与修改后的方案相比,暴发应对方案每获得一个质量调整生命年的增量成本效益比为 739063 加元(524735 欧元)。为了满足通常接受的每获得一个质量调整生命年 50000 加元(35500 欧元)的成本效益阈值,疫情应对措施必须预防 94 例麻疹病例。在敏感性分析中,研究结果是稳健的。
从医疗保健支付者的角度来看,安大略省的麻疹疫情应对措施超过了普遍接受的成本效益阈值,可能不是公共卫生资源的最有效利用。这些发现应与增加疫苗覆盖率和维持消除状态的益处相平衡。